Matinas BioPharma Holdings, Inc.Company Review & Valuation

MTNB
New York Stock Exchange
Latest Price
0.89USD
Market Capitalization
175.13mUSD

About Matinas BioPharma Holdings, Inc.

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. The company enables the delivery of life-changing medicines using its lipid nano-crystal (LNC) platform technology. Its LNC delivery technology platfoShow morerm utilizes lipid nano-crystals which can encapsulate small molecules, oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable. The company's lead anti-fungal product candidate is MAT2203, an orally-administered cochleate formulation of amphotericin B that has completed Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients with acute lymphoblastic leukemia. Its product candidates also comprise MAT2501, an orally administered cochleate formulation of the broad spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. The company was founded in 2013 and is based in Bedminster, New Jersey.Show less

Industry
Biotechnology
HQ Location
Bedminster, New Jersey

Stock Price

Price data not available for Matinas BioPharma Holdings, Inc..

Performance

Please login or create a free account to view the contents of this section.

Similar Companies

BioTime
Trevena
Codexis
Alexion Pharmaceuticals

back to top